Urologists' and GPs' knowledge of hereditary prostate cancer is suboptimal for prostate cancer counseling: A nation-wide survey in The Netherlands

Familial Cancer

Volumn 11, Issue 2, 2012, Pages 195-200

  Cremers, Ruben ^a,b   Van Asperen, Christi ^c   Kil, Paul ^d   Vasen, Hans ^b,c   Wiersma, Tjerk ^e   Van Oort, Inge ^a   Kiemeney, Lambertus ^a,f  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Netherlands Foundation for the Detection of Hereditary Tumors   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

^e DUTCH COLLEGE OF GENERAL PRACTITIONERS   (Netherlands)

^f Integraal Kankercentrum Oost   (Netherlands)

Author keywords

General practitioner; Heredity; Prostate cancer; Prostate specific antigen; Screening; Urologist

Indexed keywords

ARTICLE; BRCA2 GENE; CANCER RISK; ELAC2 GENE; FAMILIAL CANCER; FAMILY HISTORY; GENE; GENE MUTATION; GENERAL PRACTITIONER; GENETIC RISK; GENETIC SCREENING; GROUPS BY AGE; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HEREDITY; HPC1 GENE; HPC2 GENE; HPCX GENE; HUMAN; MALE; MSR1 GENE; NETHERLANDS; ONCOGENE; PATIENT COUNSELING; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; PROSTATE CANCER; RISK BENEFIT ANALYSIS; RNASEL GENE; UROLOGIST;

AGE FACTORS; AGED; CLINICAL COMPETENCE; COUNSELING; DATA COLLECTION; FAMILY; GENERAL PRACTITIONERS; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PHYSICIANS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84864647773     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-011-9500-8     Document Type: Article

References (23)

1. Brandt A, Bermejo JL, Sundquist J, Hemminki K (2010) Agespecific risk of incident prostate cancer and risk of death from prostate cancer defined by the number of affected family members. Eur Urol 58(2):275-280
2. Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, Walsh PC (1993) Hereditary prostate cancer: Epidemiologic and clinical features. J Urol 150(3):797-802
3. Langeberg WJ, Isaacs WB, Stanford JL (2007) Genetic etiology of hereditary prostate cancer. Front Biosci 12:4101-4110
4. Fletcher O, Houlston RS (2010) Architecture of inherited susceptibility to common cancer. Nat Rev Cancer 10(5):353-361
5. Varghese JS, Easton DF (2010) Genome-wide association studies in common cancers-what have we learnt? Curr Opin Genet Dev 20(3):201-209
6. Gudmundsson J, Besenbacher S, Sulem P, Gudbjartsson DF, Olafsson I, Arinbjarnarson S, Agnarsson BA, Benediktsdottir KR, Isaksson HJ, Kostic JP, Gudjonsson SA, Stacey SN, Gylfason A, Sigurdsson A, Holm H, Bjornsdottir US, Eyjolfsson GI, Navarrete S, Fuertes F, Garcia-Prats MD, Polo E, Checherita IA, Jinga M, Badea P, Aben KK, Schalken JA, van OI, Sweep FC, Helfand BT, Davis M, Donovan JL, Hamdy FC, Kristjansson K, Gulcher JR, Masson G, Kong A, Catalona WJ, Mayordomo JI, Geirsson G, Einarsson GV, Barkardottir RB, Jonsson E, Jinga V, Mates D, Kiemeney LA, Neal DE, Thorsteinsdottir U, Rafnar T, Stefansson K (2010) Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med 2(62):62-92
7. Kote-Jarai Z, Amin Al Olama A, Leongamornlert D, Tymrakiewicz M, Saunders E, Guy M, Giles GG, Severi G, Southey M, Hopper JL, Sit KC, Harris JM, Batra J, Spurdle AB, Clements JA, Hamdy F, Neal D, Donovan J, Muir K, Pharoah PD, Chanock SJ, Brown N, Benlloch S, Castro E, Mahmud N, O'Brien L, Hall A, Sawyer E, Wilkinson R, Easton DF, Eeles RA (2011) Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. Hum Genet 129(6):687-694. doi:10.1007/ s00439-011-0981-1
8. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317(15):909-916
9. Roobol MJ, Kerkhof M, Schroder FH, Cuzick J, Sasieni P, Hakama M, Stenman UH, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis L, Recker F, Berenguer A, Ruutu M, Kujala P, Bangma CH, Aus G, Tammela TL, Villers A, Rebillard X, Moss SM, de Koning HJ, Hugosson J, Auvinen A (2009) Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 56(4):584-591
10. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der KT, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13):1320-1328
11. Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13):1310-1319
12. Schroder FH, Roobol MJ (2010) ERSPC and PLCO prostate cancer screening studies: What are the differences? Eur Urol 58(1):46-52
13. Kiemeney LA, Broeders MJ, Pelger M, Kil PJ, Schroder FH, Witjes JA, Vasen HF (2008) Screening for prostate cancer in Dutch hereditary prostate cancer families. Int J Cancer 122(4): 871-876
14. Valeri A, Cormier L, Moineau MP, Cancel-Tassin G, Azzouzi R, Doucet L, Baschet F, Cussenot I, L'Her J, Berthon P, Mangin P, Cussenot O, Morin JF, Fournier G (2002) Targeted screening for prostate cancer in high risk families: Early onset is a significant risk factor for disease in first degree relatives. J Urol 168(2):483-487. doi:S0022-5347(05)64663-0
15. Bratt O, Garmo H, Adolfsson J, Bill-Axelson A, Holmberg L, Lambe M, Stattin P (2010) Effects of prostate-specific antigen testing on familial prostate cancer risk estimates. J Natl Cancer Inst 102(17):1336-1343. doi:10.1093/jnci/djq265
16. Dutch Association of Urology (2009) Public statement on the point of view regarding the results of the European randomised study of screening for prostate cancer (in Dutch). Available at: Http://www. nvu.nl/leden/nieuws/proxy? urlProxy=/root/news4/standpuntbepaling-nederlandse-vereniging-voor-urologie- Aangaande-resultaten-van-eu ropees-screeningsonderzoek-voor- prostaatkanker&objectSynopsis= 27dvQhiqyaNz7FDkExL3dA#SAHIZdeHA0JqE2GGNUP6ng. Date accessed 11 Oct 2011
17. Cremers RG, van Asperen CJ, Kil PJ, Vasen HF, Wiersma T, van Oort IM, Kiemeney LA (2011) Online survey (in Dutch). Available at: Http://www. prostaatkanker-erfelijkheidenscreening. nl/vragenlijst/prca.htm. Date accessed 11 Oct 2011
18. Liede A, Karlan BY, Narod SA (2004) Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: A review of the literature. J Clin Oncol 22(4):735-742
19. Narod SA, Neuhausen S, Vichodez G, Armel S, Lynch HT, Ghadirian P, Cummings S, Olopade O, Stoppa-Lyonnet D, Couch F, Wagner T, Warner E, Foulkes WD, Saal H, Weitzel J, Tulman A, Poll A, Nam R, Sun P, Danquah J, Domchek S, Tung N, Ainsworth P, Horsman D, Kim-Sing C, Maugard C, Eisen A, Daly M, McKinnon W, Wood M, Isaacs C, Gilchrist D, Karlan B, Nedelcu R, Meschino W, Garber J, Pasini B, Manoukian S, Bellati C (2008) Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer 99(2):371-374
20. Grindedal EM, Moller P, Eeles R, Stormorken AT, Bowitz-Lothe IM, Landro SM, Clark N, Kvale R, Shanley S, Maehle L (2009) Germ-line mutations in mismatch repair genes associated with prostate cancer. Cancer EpidemiolBiomarkers Prev 18(9): 2460-2467
21. Gronberg H, Damber L, Tavelin B, Damber JE (1998) No difference in survival between sporadic, familial and hereditary prostate cancer. Br J Urol 82(4):564-567
22. Kupelian PA, Reddy CA, Reuther AM, Mahadevan A, Ciezki JP, Klein EA (2006) Aggressiveness of familial prostate cancer. J Clin Oncol 24(21):3445-3450
23. Kranse R, Roobol M, Schroder FH (2008) A graphical device to represent the outcomes of a logistic regression analysis. Prostate 68(15):1674-1680